RVMD - Revolution Medicines Inc. (RVMD) Q1 2024 Earnings Call Transcript
2024-05-08 21:11:09 ET
Revolution Medicines, Inc. (RVMD)
Q1 2024 Results Conference Call
May 08, 2024 04:30 PM ET
Company Participants
Erin Graves - Senior Director, Corporate Communications and Investor Relations
Dr. Mark Goldsmith - Chairman and Chief Executive Officer
Jack Anders - Chief Financial Officer
Dr. Steve Kelsey - President of R&D
Dr. Wei Lin - Chief Medical Officer
Conference Call Participants
Marc Frahm - TD Cowen
Michael Schmidt - Guggenheim Securities
Eric Joseph - JPMorgan
Jonathan Chang - Leerink Partners
Ellie Merle - UBS
Poorna Kannan - Needham & Company
Alec Stranahan - Bank of America
Laura Prendergast - Raymond James
Ben Burnett - Stifel
Presentation
Operator
Good day and thank you for standing by. Welcome to Revolution Medicine's First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there'll be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker today, Erin Graves, Senior Director of Corporate Communications and Investor Relations, please go ahead.
Erin Graves
Thank you, and welcome, everyone, to the first quarter 2024 earnings call. Joining me on today's call are Dr. Mark Goldsmith, Revolution Medicine's Chairman and Chief Executive Officer; and Jack Anders, our Chief Financial Officer.; Dr. Steve Kelsey, our President of R&D will also join us for the Q&A portion of today's call.
As we begin, I would like to note that our presentation will include statements regarding the current beliefs of the Company with respect to our business that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These statements are subject to a number of assumptions, risks, and uncertainties.
Actual results may differ materially from these statements and except as required by law, the Company undertakes no obligation to revise or update any forward-looking statements. I encourage you to review the legal disclaimer in our corporate presentation and our earnings press release, as well as all of the Company's filings with the SEC concerning these and other matters.
With that, I will turn the call over to Dr. Mark Goldsmith, Revolution Medicine's Chairman and Chief Executive Officer. Mark?...
Revolution Medicines, Inc. (RVMD) Q1 2024 Earnings Call Transcript